BG Medicine in new fundraising

BG Medicine, a Waltham biotech company, raised $40 million in its latest round of venture capital, in addition to $52 million it had previously raised.

The company had originally tried to raise money through an initial public offering, but yanked the IPO filing in January citing market turmoil. No venture-backed companies have been able to go public so far this year in Massachusetts.

BG, which has 39 employees, is trying to develop novel medical tests for congestive heart failure and other maladies based on proteins and other molecules found in the body.

The company said the round included several investors: Legg Mason Capital Management, GE Asset Management and Smallcap World Fund, Flagship Ventures, Gilde Healthcare Partners, Humana and Stelios Papadopoulos.
(By Todd Wallack, Globe Staff)